Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Current data are insufficient to recommend either for or against using convalescent plasma to treat patients who have COVID-19, the National Institutes of Health's (NIH) COVID-19 Treatment Guidelines Panel said Tuesday.
"Convalescent plasma should not be considered standard of care for the treatment of patients with COVID-19," the committee said.
The NIH statement comes just more than a week after the US Food and Drug Administration (FDA) on August 23 issued an emergency use authorization (EUA) promoting the use of convalescent plasma in treating patients hospitalized with COVID-19. In the FDA statement announcing the EUA, Health & Human Services Secretary Alex Azar called it "a milestone achievement."
The COVID-19 Treatment Guidelines Panel, made up of physicians, statisticians, and other experts, rejected that interpretation of the data.
"Convalescent plasma should not be considered standard of care for the treatment of patients with COVID-19," the committee said.
The NIH statement comes just more than a week after the US Food and Drug Administration (FDA) on August 23 issued an emergency use authorization (EUA) promoting the use of convalescent plasma in treating patients hospitalized with COVID-19. In the FDA statement announcing the EUA, Health & Human Services Secretary Alex Azar called it "a milestone achievement."
The COVID-19 Treatment Guidelines Panel, made up of physicians, statisticians, and other experts, rejected that interpretation of the data.
NIH Panel Counters FDA: No Solid Data on Plasma for COVID-19
The statement from the NIH's COVID-19 Treatment Guidelines Panel comes a week after the FDA issued an emergency use authorization for treating patients hospitalized with COVID-19.
www.medscape.com